Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-03-24FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVEGA (paliperidone) from Janssen Pharmaceuticals, Inc. This action approves changes descri…
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia [Phase 3]
A Phase 3 trial evaluating cariprazine in a dose-reduction strategy for relapse prevention in schizophrenia was terminated; results were pos…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Telmisartan Pilot Study on Treatment Resistant Schizophrenia [Phase 2]
Phase 2 pilot study on telmisartan for treatment-resistant schizophrenia was terminated with posted results.
-
FDA approval · 2022-02-28FDA Approved: THIOTHIXENE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for thiothixene, a generic antipsychotic, submitted by Amneal Pharmaceuticals NY LLC.
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension [Phase 3]
Open-label extension of a Phase 3 trial evaluating risperidone ISM in acute schizophrenia; study completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) [Phase 3]
Phase 3 trial evaluating efficacy and safety of asenapine using an active control in adults with schizophrenia or schizoaffective disorder; …
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784) [Phase 3]
Phase 3 long-term efficacy and safety trial evaluating asenapine with olanzapine as a positive control in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients [Phase 4]
Phase 4 trial updating a comparison between berberine and metformin for metabolic syndrome in schizophrenia patients.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Targeting Auditory Hallucinations With Alternating Current Stimulation [NA]
A completed clinical trial investigating alternating current stimulation for auditory hallucinations in schizophrenia/schizoaffective disord…
-
CLINICAL_TRIALS trial_result · 2022-02-09Clinical Trial Update: An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia [Phase 2]
An extension Phase 2 study evaluating the safety and tolerability of SEP-363856 in adults with schizophrenia has completed, with results pos…
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia [Phase 3]
Phase 3 trial assessing efficacy and safety of Risperidone in Situ Microparticle (ISM) for acute schizophrenia has completed with results po…
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Improving Accessibility and Personalization of CR for Schizophrenia [NA]
A completed clinical trial exploring accessibility and personalization of cognitive rehabilitation for schizophrenia and schizoaffective dis…
-
FDA approval · 2022-01-28FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2022-01-13FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for lurasidone hydrochloride submitted by Accord Healthcare, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-12Clinical Trial Update: A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis [Phase 1, Phase 2]
A placebo-controlled study of IV ceftriaxone for refractory psychosis was terminated; results were posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia [Phase 4]
Phase 4 clinical trial assessing computerized cognitive remediation therapy for schizophrenia completed; results not provided in snippet.
-
CLINICAL_TRIALS trial_result · 2021-12-22Clinical Trial Update: Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of WID-RGC20 (Cariprazine) in patients with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2021-12-17Clinical Trial Update: MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics [Phase 4]
Phase 4 trial update evaluating maintenance of efficacy and safety after switching to a long-acting injectable aripiprazole from oral atypic…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: A Study of Paliperidone Palmitate 6-Month Formulation [Phase 3]
Phase 3 trial of paliperidone palmitate 6-month formulation for schizophrenia has been completed. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia [Phase 3]
Phase 3 trial evaluating TV-46000 as maintenance treatment in adults and adolescents with schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia [NA]
Clinical trial update on transcranial magnetic stimulation for treating auditory hallucinations in schizophrenia; study terminated with resu…
-
FDA approval · 2021-11-29FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Chartwell RX, LLC)
FDA approved chlorpromazine hydrochloride from Chartwell RX, LLC under an original ANDA for generic use.
-
FDA approval · 2021-11-19FDA Approved: OLANZAPINE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for Olanzapine from Macleods Pharmaceuticals Limited.
-
FDA approval · 2021-11-18FDA Approved: OLANZAPINE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for a generic olanzapine product from Upsher-Smith Laboratories, LLC (ANDA204319).
-
FDA approval · 2021-11-12FDA Approved: QUETIAPINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for a generic quetiapine product (ANDA204203). This marks a supplemental ap…